In this new study, iLite® VEGF responsive cells and iLite® ADCC (antibody-dependent cell-mediated cytotoxicity) BIOASSAYS were used to study bevacizumab's neutralizing activity of VEGFA.
According to the study, despite variations in treatment methods and indications, a strong correlation exists between the neutralizing and ADCC activities of bevacizumab and the circulating drug levels.